Dosing & Administration for Migraine


Emgality offers a once-monthly, self-administered subcutaneous injection1

The Emgality Pen1:

  • Once-monthly dosing
  • No titration required
  • Latex-free
Emgality Pen Image

Recommended dosing with no titration required1a

Month 1: Initial loading dose of two 120 mg injections
Subsequent months: One 120 mg injection per month

A loading dose of 240 mg resulted in steady-state Emgality concentrations after the first dose.1

Emgality Pens Dosing image

With the Emgality loading dose, 15% of patients’ first-year therapy is administered on Day 1.1b

aThe Emgality Pen needle is 27 gauge x 1/2 inch.2

bCalculation: 240 mg loading dose + 120 mg/month x 11 months=1560 mg; 240 mg/1560 mg=0.1538 (15%).1

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019